Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
Apatinib is a new kind of Vascular endothelial growth factor receptor(VEGFR) tyrosine kinase
inhibitors (TKIs). The investigators have finished the preclinical and phase I and phase II
clinical study for apatinib and found its satisfactory anti-tumor activity and tolerated
toxicities. A disease-control rate of 75% was found in lung cancer patients. In the present
phase III trial, the investigators will further evaluate the efficacy and toxicities of
apatinib in the treatment of advanced non-squamous non-small cell lung cancer.